Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Romosozumab Has Biggest BMD Benefit in First Year of Treatment

Anne Harding  |  

Amgen, USB Pharma and Astellas funded the study, and Dr. McClung and other study authors report financial relationships with Amgen and other drug companies.

Reference

ADVERTISEMENT
SCROLL TO CONTINUE
  1. McClung MR, Brown JP, Diez-Perez A, et al. Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: A randomized, double-blind, phase 2, parallel group study. Journal of Bone Mineral Research. 2018 Apr 25. [Epub ahead of print]

Related Articles

    Novel Bone Drug Promising in Postmenopausal Osteoporosis

    NEW YORK (Reuters Health)—The investigational drug romosozumab led to gains in hip bone mineral density (BMD) that were not seen with teriparatide in older women with osteoporosis transitioning from bisphosphonate therapy in the STRUCTURE study. Amgen’s romosozumab is a monoclonal antibody that inhibits sclerosin, a negative regulator of bone formation. In addition to stimulating bone…

    Rheumatology Drug Updates: Etanercept for Pediatric Plaque Psoriasis

    Etanercept Submitted for Chronic, Severe Plaque Psoriasis in Children The U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application for etanercept (Enbrel) for treating pediatric patients with chronic, severe plaque psoriasis.1 The application was submitted in early January 2016 and is based on results of a one-year Phase 3 study with…